InvestorsHub Logo
Followers 260
Posts 18196
Boards Moderated 0
Alias Born 01/19/2006

Re: DewDiligence post# 488

Friday, 10/04/2019 8:58:05 PM

Friday, October 04, 2019 8:58:05 PM

Post# of 875
"A combination with Zocor[a statin] might make sense, but Zocor has been off-patent for several years, and MRK no longer has any interest in it."

IMO, MRK might well be interested in buying Amarin, with AMRN's NCE status for Vascepa, a patent portfolio encompassing Vascepa + statins extending to 2030, analyst projections of market/revenue size, continued increase in prescriptions as well as market share[now > %50% vis a vis Lovaza or gLovaza], and PTs of $30-50 per share reflecting Vascepa market of > $10B. My own off-label scrip for FDA-approved Vascepa of 6+ years duration has resulted, in light of insurance coverage, in my total co-pay of $36/year.

Original post in this thread, all links included:

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=151534457
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MRK News